Ixico PLC (LON:IXI) said it is providing funding and expertise for the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Two of the neuroscience analytics company's scientists will join the private partner scientific board of ADNI, which is a longitudinal multicentre study looking to develop clinical, imaging, genetic and biochemical biomarkers for the early detection and tracking of Alzheimer's disease.
ADNI aims to achieve its goals through the application of new diagnostic methods in a “pre-competitive environment” and through its partners sharing data to advance the field.
The private partner scientific board is designed to facilitate "open dialogue" around any progress made within the ADNI project and around new trends with Alzheimer's disease-related research and development.
AIM-listed Ixico specialises in data analytics services that identify and measure unique biomarkers from brain scan and wearable biosensor data produced in clinical research programmes.
Ixico chief executive Giulio Cerroni said: “We are proud to support the ADNI initiative which has made a major contribution to setting the imaging standards in AD research and provides access to important clinical data sets to the global research community.
“ADNI's purpose is well-aligned with our own goal to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare which will contribute to the advancement of AD research.
“We look forward to engaging with all members of the consortium to contribute to the success of this initiative.”